GlaxoSmithKline (GSKN) AI Stock Analysis

GlaxoSmithKline

(BMV:GSKN)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Specialty medicines growth and pipeline expansionStrong specialty-medicine growth and a materially accelerated phase III programme broaden GSK’s future product base. Continued launches, approvals and late-stage development can improve the mix toward higher-growth franchises and support revenue durability over the coming years.

Negative Factors

Elevated leverage and rising financing costsDebt-dependent financing reduces flexibility compared with a conservative balance sheet and makes earnings more sensitive to interest costs. The Nuvalent-related expense and projected higher future interest burden could constrain cash available for pipeline investment and capital returns.

GlaxoSmithKline (GSKN) vs. SPDR S&P 500 ETF (SPY)

Market Cap: MXN 99.24B
Dividend Yield: 3.38%
Average Volume (3M): 46
Price to Earnings (P/E): 17.2
Beta (1Y): 0.21
Revenue Growth: -3.91%
EPS Growth: -26.26%
Country: Mexico
Employees: 66,841
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - General

GlaxoSmithKline Business Overview & Revenue Model

Company Description

GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known...

GlaxoSmithKline Earnings Call Summary

Earnings Call Date:Oct 27, 2026(Q3-2026)|% Change Since:9.58%|Next Earnings Date:Feb 02, 2027

Earnings Call SentimentPositive

The call was strongly positive overall. GSK reported 5% sales growth, reaffirmed 2026 guidance, delivered strong cash generation, and highlighted substantial progress across launches, approvals, commercial growth, and the accelerated phase III pipeline. The main negatives were vaccine and inhaler market pressures, significant restructuring and financing costs, foreign exchange headwinds, ongoing uncertainty around the four-monthly APRETUDE formulation, and adoption or monitoring challenges for certain products.

Positive Updates

Q3 Sales and Operating Momentum

Q3 sales increased 5% to GBP 8.9 billion, core operating profit grew 5%, and core EPS increased 1%. Specialty medicines drove momentum, with specialty sales up 15%.

Negative Updates

Vaccine Revenue Decline

Vaccine performance declined 2% in the quarter, primarily because of Shingrix China destocking, which was only partly offset by U.S. growth.

Company Guidance

GSK reconfirmed 2026 guidance, with sales expected in the upper half of the range, Core operating profit also expected in the upper half of the range, and margin on track to be more than 31% at constant rates; SG&A is projected to be broadly stable, royalties are now upgraded to around GBP 900 million for the year, R&D is expected to grow significantly ahead of sales as phase III starts increase from the 10 expected at the start of the year to now 22, EPS growth is expected to be in the low half of the range, full year interest is expected to be GBP 700 million-GBP 750 million, including around GBP 160 million relating to the acquisition of Nuvalent, and foreign exchange headwinds are expected to be -1% on sales and -3% on operating profit; GSK expects charges of up to GBP 1 billion in 2026 and remains on track to deliver a target of around GBP 10 billion CGFO at constant rates.

GlaxoSmithKline Risk Analysis

GlaxoSmithKline disclosed 1 risk factors in its most recent earnings report. GlaxoSmithKline reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

1 New Risk

1.Text to select risk factors from:Q4, 2024

GlaxoSmithKline Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

MX:GSKN against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PFE	74Outperform	$173.95B	40.33	4.89%	5.64%	-0.21%	-59.71%
NVS	72Outperform	$296.91B	31.19	24.24%	2.95%	1.64%	-28.72%
SNY	71Outperform	$106.82B	24.39	5.52%	5.46%	23.68%	-30.90%
JNJ	70Outperform	$657.68B	41.42	19.55%	1.93%	7.81%	-35.95%
MRK	63Neutral	$368.89B	152.57	5.10%	2.27%	5.16%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

MX:GSKN and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
MX:GSKN	GlaxoSmithKline	938.00	101.45	12.13%
JNJ	Johnson & Johnson	273.20	91.04	49.98%
MRK	Merck & Company	149.52	69.38	86.58%
NVS	Novartis AG	160.79	39.31	32.36%
PFE	Pfizer Inc	30.52	7.48	32.45%
SNY	Sanofi SA	44.34	-3.79	-7.87%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

GlaxoSmithKline AI Stock Analysis